![]() | Only 14 pages are availabe for public view |
Abstract Infectious diseases represent an important cause of morbidity and mortality among the general population, particularly in developing countries. Therefore, pharmaceutical companies have been motivated to develop new antimicrobial drugs in recent years, especially due to the constant emergence of microorganisms resistant to conventional antimicrobials. Apparently, bacterial species present the genetic ability to acquire and transmit resistance genes against currently available antibacterials since there are frequent reports on bacterial isolation that were known to be sensitive to routinely used drugs and became multi-drug resistant. Consequently, common strategies adopted by pharmaceutical companies to supply the market with new antimicrobial drugs include changing the molecular structure of the existing medicines in order to make them more efficient or recover the activity lost due to bacterial resistance mechanisms.In the same contest, given the search for new antimicrobials, those of plant origin must be emphasized since Egypt possess such great biodiversity with a large number of plants which have been used for diverse purposes throughout the globe for hundreds of years. |